$BRTX News

Last published 2mo ago

2mo agoBRTXBioRestorative Therapies Announces Reverse Stock SplitGlobeNewswireMELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced
4mo agoBRTXBioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics PlatformGlobeNewswireMELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (NASDAQ:BRTX), a late-stage clinical regenerative medicine company
4mo agoBRTXBioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic GrowthGlobeNewswireAccomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the
5mo agoBRTXBioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobeNewswireFully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeting alignment
6mo agoBRTXBioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsGlobeNewswireData demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative
6mo agoBRTXBioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseGlobeNewswireOral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiting toxicity safety
6mo agoBRTXBioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformGlobeNewswireData demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
6mo agoBRTXBioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformGlobeNewswireCollaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across professional, biologic
7mo agoBRTXBioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformGlobeNewswirePartnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare MELVILLE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) --
7mo agoBRTXBioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseGlobeNewswireData showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells Presented
8mo agoBRTXBioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026GlobeNewswireCompany to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
8mo agoBRTXBioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital StrategyGlobeNewswireCompany is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build
8mo agoBRTXBioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 DrugsGlobeNewswireGLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may
9mo agoBRTXBioRestorative Announces Closing of $5.0 Million Public OfferingGlobeNewswireMELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem
9mo agoBRTXBioRestorative Announces Pricing of $5.0 Million Public OfferingGlobeNewswireMELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem
9mo agoBRTXBioRestorative Announces Positive Outcome from Type B Meeting with FDAGlobeNewswireBioRestorative completed a Type B meeting with the U.S. Food and Drug Administration ("FDA") regarding a potential accelerated Biologics License Application ("BLA") approval pathway for the Fast-Track-Designated BRTX-100
9mo agoBRTXBioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc DiseaseGlobeNewswireLargest FDA-authorized Phase 2 cell therapy trial conducted in chronic lumbar disc diseaseThe study has enrolled a total of 99 participants, each of whom was randomized to receive either BRTX-100 or placeboProspective,
11mo agoBRTXBioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc DiseaseGlobeNewswireMELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
12mo agoBRTXBioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireMELVILLE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025GlobeNewswireMELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug MarketGlobeNewswireMELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product PortfolioGlobeNewswireMELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Therapies to Participate in the 2025 Maxim Growth SummitGlobeNewswireMELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show"GlobeNewswireMELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above MarketGlobeNewswireMELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced
1y agoBRTXBioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoBRTXBioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireMELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025GlobeNewswireMELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updatesGlobeNewswireMELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Announces Share Repurchase ProgramGlobeNewswireMELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc DiseaseGlobeNewswire– The International Society for Stem Cell Research ("ISSCR") 2025 Annual Meeting is the world's foremost gathering of stem cell and regenerative medicine leaders – – Updated data presented at ISSCR 2025 demonstrates
1y agoBRTXBioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX TeamGlobeNewswireMELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025GlobeNewswire– New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from
1y agoBRTXBioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireMELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXPhase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded DataGlobeNewswireMELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025GlobeNewswireMELVILLE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025GlobeNewswireMELVILLE, N.Y., May 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial OpportunitiesGlobeNewswireMELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United StatesGlobeNewswireMELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Therapies Reports 2024 Financial Results and Provides Business UpdateGlobeNewswireMELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and
1y agoBRTXBioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025GlobeNewswireMELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic PainGlobeNewswire– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company's advanced clinical pipeline for BRTX-100
1y agoBRTXBioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline UpdateGlobeNewswireMELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative to Provide a Positive FDA Update on Clinical PipelineGlobeNewswireMELVILLE, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
1y agoBRTXBioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease ProgramGlobeNewswire– Underscores high unmet need for a therapeutic alternative to opioids and surgical interventions – – Reflects positive preliminary Phase 2 Safety and Efficacy data reported to date – – May also lead to Priority Review
1y agoBRTXBRTX-100 Front and Center at ORS 2025GlobeNewswire– New blinded preliminary BRTX-100 data described this past Saturday at prestigious "2025 Winners in Industry Innovations in MSK Health" presentation – – Among other positive preliminary data analyses, comparison of MRI
1y agoBRTXBioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease ProgramGlobeNewswire– Covers cGMP manufacturing processes – – Expected to provide protection until April 29, 2040 – MELVILLE, N.Y., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the
1y agoBRTXBioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
1y agoBRTXBioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical DataGlobeNewswire– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in function – – If
1y agoBRTXBioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireMELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and